SURF1 and Leigh syndrome: Crucially, bezafibrate treatment allowed the SURF1-neurons to undergo the metabolic switch from glycolysis to OXPHOS and nearly ameliorated all mitochondrial functional defects, supporting bezafibrate as a possible therapeutic option for SURF1-related Leigh syndrome [3,99].